Express Pharma

Lupin receives US FDA approval for generic Topicort ointment

3

The ointment is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Lupin has received final approval for its Desoximetasone Ointment USP, 0.05 per cent from the United States Food & Drug Administration (US FDA) to market a generic version of Taro Pharms North’s Topicort Ointment, 0.05 per cent. The product filing is from Lupin’s Pithampur (Indore) manufacturing facility.

Lupin’s Desoximetasone Ointment USP, 0.05 per cent is the AB rated generic equivalent of Taro Pharma North’s Topicort Ointment, 0.05 per cent. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort Ointment had US sales of $12.1 million (IMS MAT September 2016).

 

Comments are closed.